Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Head and Neck Cancer - Resected Advanced Disease

Trial Name: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab For Locally-Advanced Resected Head and Neck Cancer.

Protocol ID: RTOG - 0920

Eligibility:

  • Pathologically (histologically) proven diagnosis of squamous cell carcinoma of the head/neck.
  • Age >18
  • Must meet required laboratory values
  • Women of childbearing potential and male participants who are sexually active must agree to use medically effective means of birth control.
Ineligibility:
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago. Patients with simultaneous primaries or bilateral tumors are excluded.
  • Prior systemic chemotherapy or anti-EGF therapy for the study cancer; note: prior chemotherapy or anti-EGF therapy for a different cancer is allowable.
  • Prior radiation therapy to the region of the study cancer that would result in overlap of radiation fields.
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.

Prior allergic reaction to cetuximab

Enrollment: • About 700 people will take part in this study at several medical centers.

Benefits:

Taking part in this study may or may not make your health better. While doctors hope radiation therapy with or without cetuximab may keep your head and neck cancer from growing, there is no proof of this yet. The effects of a combination of radiation and cetuximab may be no different or worse than radiation alone. We do know that the information from this study will help doctors learn more about these therapies as a treatment for cancer. This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jun 3, 2011

Updated: Jan 18, 2013

« Return to Trials